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Tuberculosis (TB) kills more people
than any other single infection, the global
burden of TB cases and drug resistance
are increasing [1], and most patients still
only have access to an inadequate diag-
nostic test developed more than a century
ago. Recent evaluations of a desktop
machine called the GeneXpert MTB/
RIF that in less than two hours simulta-
neously detects Mycobacterium tuberculosis
and tests for drug resistance have stimu-
lated tremendous enthusiasm [2,3]. Is this
the breakthrough that TB control has
been waiting for?
The Backstory
TB has non-specific clinical features, so
diagnosis usually requires laboratory test-
ing. Traditional sputum smear microscopy
is the only laboratory test for TB that is
accessible to most of the world’s population.
Smear microscopy is inexpensive, appro-
priate for basic laboratories, rapidly diag-
noses the most infectious patients, and has
high specificity, so positive results almost
always prompt treatment. However, smear
microscopy has two key inadequacies: (1) it
is insensitive, prone to false-negative
‘‘smear-negative TB’’ results; and (2) it
cannot test for drug resistance, which is
important because patients with drug-
resistant TB require prompt second-line
treatment to prevent morbidity, mortality,
and dissemination of increasingly resistant
multi-drug-resistant tuberculosis (MDRTB)
and extensively drug-resistant tuberculosis
(XDRTB) [4,5]. Traditional TB culture for
diagnosing smear-negative TB and testing
for drug resistance takes weeks, too slow to
adequately address these inadequacies.
Newer rapid tests for TB and drug
resistance such as MODS, Griess, MGIT,
thin-layer agar, colorimetric assays, and
some molecular tests [6,7] are potential
solutions but require specialised laborato-
ries and skills that are often unavailable in
the regions where most cases of TB and
MDRTB occur [1].
The GeneXpert MTB/RIF Test
The MTB/RIF test offers a potential
solution for improving TB diagnosis [8].
Molecular testing enables speed, and the
MTB/RIF test is feasible for use in
peripheral labs and clinics by unskilled
personnel [9]. In two multi-centre studies,
a single MTB/RIF test detected almost all
smear-positive TB patients and about
three-quarters of the smear-negative TB
patients whilst concurrently testing for
rifampicin resistance, thus identifying pa-
tients who need second-line drug treat-
ment [2,3]. By enabling TB diagnosis and
drug resistance testing almost anywhere
without requiring the specialised laborato-
ries and technicians needed for other rapid
tests [9], this new MTB/RIF test has the
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capacity to be a ‘‘game-changer’’ in TB
diagnosis.
New Research Sounds Caution
In this week’s issue of PLoS Medicine,
three new articles raise important points of
concern as the field progresses to imple-
mentation of this innovative technology.
An Achilles heel of polymerase chain
reaction tests for diagnosing TB is cross-
contamination, in which the products
from previous assays cause false-positive
results. By using sealed disposable car-
tridges, this new MTB/RIF test apparent-
ly overcomes this problem [2,3,8,10].
However, the MTB/RIF test has inter-
mediate sensitivity, better than smear
microscopy but less than broth-culture,
risking false-negative results [2,3,8,10].
Stephen Lawn and colleagues [11] report
in this issue of PLoS Medicine that a single
MTB/RIF test detected less than half of
the cases of smear-negative culture-posi-
tive TB in HIV-positive patients being
screened for TB to check whether they
could safely be provided with chemopro-
phylaxis. Thus, a single MTB/RIF assay
may be insufficient for ‘‘ruling-out’’ TB,
although a second test for each patient
increased sensitivity to 62%. Furthermore,
in this week’s issue, Lesley Scott and
colleagues [12] and Stephen Lawn’s group
[11] separately report that the MTB/RIF
assay occasionally provides incorrect as-
sessments of rifampicin resistance, princi-
pally false resistance, as has been reported
previously. Whilst these errors are uncom-
mon, they are inevitable because the speed
of genotypic testing for TB drug resistance
is a valuable but imperfect surrogate for
the slower phenotypic culture-based tests.
David Dowdy and colleagues, in a third
paper in this week’s PLoS Medicine [13],
add to the Xpert story by providing new
insights into the complexities of comparing
the benefits of increased correct diagnoses
with the adverse consequences of occa-
sional misdiagnoses, concluding that stan-
dard cost-effectiveness analyses may give
misleading results.
What about Accuracy?
The MTB/RIF test enables TB detec-
tion and rifampicin resistance testing near
the point of care, facilitating rapid screen-
ing for TB and drug resistance. However,
the accuracy issues described above sug-
gest that access to confirmatory culture-
based testing will still be required in many
settings. Rifampicin-resistant TB is usually
MDRTB and always requires second-line
drug therapy, so this has immediate
treatment implications [3,5]. Patients
found by the MTB/RIF test to have
rifampicin-resistant TB still require spe-
cialist laboratory facilities for more exten-
sive drug resistance testing. Paradoxically,
the benefit of MTB/RIF test implemen-
tation through identifying more rifampi-
cin-resistant TB is likely to actually
increase the demand for specialist refer-
ence laboratories to indicate how those
patients infected with rifampicin-resistant
TB should be treated.
Limitations of the Test
The MTB/RIF test is a major advance
in TB diagnostic testing, but has limita-
tions, including the limited shelf-life of the
diagnostic cartridges, some operating tem-
perature and humidity restrictions, require-
ment for electricity supply, unknown long-
term robustness, and the need for annual
servicing and calibration of each machine
[14]. Laboratories in low-income countries
are littered with expensive equipment that
no longer functions because it was inap-
propriate to the setting to which it was
donated. Ensuring sustainable systems for
long-term provision of servicing and con-
sumables may be more important and
challenging than initial implementation of
the diagnostic equipment itself.
Impact in Low- and
Middle-Income Settings
While effectiveness analysis and feasibil-
ity studies are necessary, they are poor
surrogates for predicting the impact of the
MTB/RIF test in programmatic use [15].
More broadly, lab-based accuracy data are
not sufficient to judge the contribution of
new diagnostic tools for case finding,
treatment, cure, and ultimately TB control.
Despite numerous microbiological studies
of improved TB diagnostic technologies, we
remain remarkably ignorant of how best to
implement better tests to improve patient
care, of who should receive the limited
capacity for better tests to maximise health
impact, of how these tests may impact
patient-relevant outcomes, and of how
these issues vary between settings [15].
The impact of better diagnostic tests on the
equity of care is largely unstudied and we
don’t know yet how this novel technology
will affect the delays and costs faced by
patients in their journey towards a cure for
this archetypal disease of poverty.
The Greatest Challenge for
GeneXpert: Case-Finding
In 2009, only 63% of all TB cases were
estimated to have been diagnosed, partly
because smear microscopy is so insensitive
that it fails to detect TB in a third of
patients who would be diagnosed by
culture [1]. Smear microscopy is particu-
larly insensitive for diagnosing TB in
patients at high risk of dying from TB,
including children and people living with
HIV [9]. However, providing TB tests that
are more sensitive than smear microscopy
is confounded by the non-specific nature
of TB symptoms—most people tested for
TB are negative by all TB tests because
they actually have other diseases, not TB
[16]. For example, in a Peruvian commu-
nity, one in 14 individuals tested for
suspected TB had positive smear micros-
copy [17]. In contrast, in the same
community, each MTB/RIF test diag-
nosed TB in one in 34 of the selected
patients with suspected TB who were
smear-negative [2]. Such statistics assess-
ing the number of tests required to impact
upon each patient-important outcome are
key to the optimal implementation of TB
diagnostics, but are rarely reported by
research studies [15]. This damaging
omission must be corrected in future
research. As with any TB test, many
people will have to be tested for each
smear-negative individual with suspected
TB diagnosed [2]. Consequently in some
settings, providing the relatively expensive
MTB/RIF test for TB case-finding may
only be sustainably affordable for selected
patient groups and may be less cost-
effective than behavioural interventions
[18] or focusing the provision of this test
for drug resistance testing.
The Ongoing Toll of Drug
Resistance
TB drug resistance prevalence is in-
creasing [1], and of the estimated 500,000
people annually who develop MDRTB,
less than 7% are diagnosed and only one
in five of these receive effective treatment
[19]. The introduction of a new diagnostic
test, no matter how good, doesn’t neces-
sarily imply clinical benefit because better
TB tests only lead to better health if
populations can afford to access them and
act effectively upon their results. Indeed,
studies frequently report success diagnos-
ing MDRTB and XDRTB cases that then
remain untreated [20–22] despite the
demonstrated achievability of effective
MDRTB care [23,24]. Clearly, the cur-
rent widespread failure to adequately
manage the great majority of the MDRTB
that is already diagnosed is no justification
for failing to diagnose the rest. To be sure,
increasing universal rapid MDRTB diag-
nosis is important for meeting the human
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rights and public health needs for univer-
sal access to MDRTB treatment and the
MTB/RIF test has the capacity to greatly
facilitate this process. However, six-
months curative treatment for a TB
patient costs a few tens to a few hundreds
of dollars, but MDRTB treatment costs
ten to a hundred times more, several
thousands of dollars [25]. Thus, in many
settings, the costs of MTB/RIF testing are
likely to be dwarfed by the cost of treating
the drug-resistant TB that it will diagnose.
Furthermore, MDRTB management
requires skills and specialist drug supply
that currently have severely restricted
availability in the low-income countries
where most MDRTB occurs [1]. Conse-
quently, the greatest challenges concern-
ing MTB/RIF screening of new TB
patients for drug resistance will likely be
to ensure rapidly expanded capacity to
manage drug-resistant TB. The early
diagnosis of drug-resistant TB can be
cost-effective [25], but risk factors for TB
drug resistance have poor predictive value,
especially in high-prevalence settings [26],
so universal drug resistance testing of all
new TB patients by the MTB/RIF or
other rapid tests is a priority in many
settings. Despite these challenges, the
global public health community will be
wise to take the opportunity offered by
rapid MDRTB tests, including the MTB/
RIF test, to urgently invest in preventing
the global increase in drug-resistant TB.
Cost Will Always Be Key
An important limitation of the MTB/
RIF test is its cost, which may be
prohibitive for a disease that principally
affects poor people in poor communities
[9]. With tiered pricing for low-income
countries, each MTB/RIF test machine
currently costs US$17,000–$62,000. More
importantly, each disposable test-cartridge
costs US$17–$120 [27], which is compa-
rable with the per capita annual health
expenditure in the countries with the
highest TB burdens. Although much more
expensive than smear microscopy, afford-
ability varies greatly between settings,
these costs are expected to fall, and they
appear to be comparable with the total
costs of providing other rapid TB tests
[27]. Furthermore, experiences with HIV
viral load and CD4 cell counting tests have
demonstrated that advocacy can convince
donors to fund the rapid implementation
of relatively expensive diagnostic technol-
ogies when needs and benefits are clear,
and the MTB/RIF test may be such a test.
Thus, costliness may not prevent the roll-
out of this test to the limited numbers of
TB patients requiring drug resistance
testing, but may severely restrict the
availability of this assay for the much
larger numbers of people needing testing
for suspected TB. Despite the fact that
funding for TB control in high-burden
countries has more than doubled between
2002 and 2009, large funding gaps
remain, and many countries are currently
struggling to sustain basic diagnostic and
treatment services. For example, it has
been estimated that in India, providing the
MTB/RIF test to only 15% of the
suspected cases of TB would consume
the annual budget for the entire TB
control program [13].
Conclusion
The MTB/RIF test should make rapid
drug resistance testing more widely achiev-
able and, in selected groups, may strength-
en TB case finding. Its impact will
inevitably be limited by its expense, but
it may be cost-effective and useful for
rapidly screening TB patients for drug
resistance if funding for increased MDR
TB treatment also becomes available.
Whilst this advance should be celebrated
and funding for it should be prioritised,
this must be viewed within the shameful
context that almost 2 million people die
each year from TB, and very few of them
would have been saved by any diagnostic
test. Specifically, these deaths occur in
mainly HIV-negative people, almost all of
whom die from drug-susceptible TB,
principally because of the inadequacy of
basic, inexpensive health care provision
for this curable infectious disease. Funding
should be identified to make the MTB/
RIF test available in suitable settings, but
the current financial crisis coupled with
the huge unmet needs in other health
areas will make the competition for
resources even more intense [28]. This
new test must not divert resources from
preventive efforts and well-established TB
diagnostic and treatment systems that
already have the potential to have consid-
erable impact upon TB morbidity and
mortality.
TB control programs have ‘‘averted
millions of deaths, but their effects on TB
transmission and incidence rates are not
yet widely detectable’’ [29]. Poverty and
social factors remain the principal deter-
minants of global TB rates, not TB control
efforts [29,30]. There is increasing con-
sensus that tools such as the new MTB/
RIF test must be integrated with interven-
tions that address the socioeconomic
determinants of TB [28,31–33] if they
are to help current achievements in TB
care to result in TB control.
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